炎症性蛋白质特征与高水平的里瓦洛克萨班暴露有关
Catherine Feliu1, Jean Escal2, Cyril Leven3
1Université de Reims Champagne Ardenne, UR 3801 PPF, Reims 51100, France; Centre Hospitalier Universitaire de Reims, Service Pharmacologie-Toxicologie, Pôle de Biologie Territoriale, Reims 51100, France.
Biochemical pharmacology
|December 23, 2025
概括
系统性炎症,由高C反应蛋白 (CRP) 表示,可能导致更高的Rivaroxaban药物水平. 这一发现表明,CRP可以帮助个性化抗凝剂治疗,以获得更好的患者结果.
科学领域:
- 药理学和蛋白质组学 药理学和蛋白质组学
- 临床化学和生物标志物
背景情况:
- 像里瓦洛克萨班这样的直接口服抗凝剂对患者的暴露是可变的,这会影响疗效和安全性.
- 现有的遗传和临床因素不能完全解释这种变异性.
- 识别新的因素对于优化抗凝剂治疗至关重要.
研究的目的:
- 调查与里瓦洛克萨班暴露水平相关的全身蛋白质特征.
- 探索炎症在里瓦洛克萨班药理学中的作用.
主要方法:
- 在64名参与者中使用液体染色学质谱法进行等离子体蛋白质组分析.
- 分为高和低利瓦洛克萨班暴露组的分层.
- 使用向C反应蛋白 (CRP) 和细胞因子测试进行验证.
主要成果:
- 蛋白质组分析确定了与高水平的里瓦洛克萨班暴露相关的炎症和血管相关的蛋白质.
- 在高暴露组中,C-反应蛋白 (CRP) 和脂蛋白 (LPA) 显著增加.
- 在药物暴露较高的患者中观察到一种促炎性细胞因子 (cytokine) 概况.
结论:
- 系统性炎症,特别是CRP升高,与增加的里瓦洛克萨班暴露有关.
- CRP显示出作为个性化抗凝剂剂量策略的生物标志物的潜力.
- 进一步的研究可以完善针对抗凝血的个性化医学方法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
The JAK-STAT Signaling Pathway
11.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.8K
Inflammatory Response I: Vascular and Cellular
15.8K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
15.8K
Inflammatory Response II: Inflammatory Exudate and Tissue Repair
7.2K
The immune system's inflammatory response destroys the invading pathogen, permitting the tissue to heal. The changes during the cellular and vascular stages allow exudate formation at the site of inflammation. The inflammatory exudate released from the wound has high protein content and a specific gravity above 1.020.
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
7.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
266
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
266


